Review: Normal V. Elevated D-dimers and “D-dimeritis”

Here’s a thought-provoking 2022 D-dimer review available from your medical library: Thachil J, Favaloro EJ, Lippi G. D-dimers-“normal” levels versus elevated levels due to a range of conditions, including “D-dimeritis,” inflammation, thromboembolism, disseminated intravascular coagulation, and COVID-19. Semin Thromb Hemost. 2022;48(6):672–9. doi: 10.1055/s-0042-1748193. PMID: 35803265. Abstract D-dimers reflect a breakdown product of fibrin. The current […]

Comments (0)

Fibrinolysis

Mar 22 2026

george

Case Study: VWF Inhibitors in Brothers

This open-access article describes inhibitor formation in two brothers who were subjects in a Wilate® study: Djambas Khayat C, Pavlova A, Werner S, Knaub S, Sidonio RF Jr. von Willebrand factor (VWF) inhibitors in two brothers with von Willebrand disease: a case report. TH Open. 2025;9:a26069625. doi: 10.1055/a-2606-9625. PMID: 40673043; PMCID: PMC12265396. Abstract The development […]

Bleeding Disorders

Meta-analysis: BAT in VWD Dx

At the March 18–21, 2026 THSNA meeting in Portland, Oregon, USA, there were several oral and poster presentations on VWD symptoms, management, and laboratory diagnosis and monitoring. Here is an open-access meta-analysis on BAT efficacy in VWD: Kalot MA, Husainat N, Tayiem S, et al. Bleeding assessment tools in the diagnosis of VWD in adults […]

Bleeding Disorders

Review and History: Protamine and Gene Therapy

Here is a provocative article available from your medical library: Thachil J. Protamine–the journey from DNA to heparin neutralization to gene therapy. Semin Thromb Hemost. 2022;48:240-243. doi: 10.1055/s-0041-1736574. PMID: 34729729. Abstract Protamine is now well recognized as a key heparin-neutralizing agent. However, protamine was discovered over a century ago, during experiments performed to uncover the […]

Comments (0)

Anticoagulant Therapy

Mar 14 2026

george

Review: Antiphospholipid Antibodies and Cardiovascular Thrombosis

Go to your medical library for this pre-print review: Rashedi S, Leyva H, Siddiqui SA, et al. Antiphospholipid antibodies and cardiovascular thrombosis. Nat Rev Cardiol. 2026. doi: 10.1038/s41569-026-01269-9. PMID: 41807758. Abstract Antiphospholipid antibodies (aPL) are directed against phospholipids and phospholipid-binding proteins. Laboratory assays used to detect aPL include serological tests for aPL against β2-glycoprotein 1, […]

Thrombophilia

Effects of Platelet Transfusions on Neonates

Check your medical library for this article that describes levels of morbidity and mortality of neonates receiving platelet transfusions: Davenport P, Feldman HA, Young V, et al. Effects of platelet transfusions on neonatal bleeding and inflammation. Pediatr Res. 2025 Nov 5. doi: 10.1038/s41390-025-04498-9. Erratum in: Pediatr Res. 2025 Dec 2. doi: 10.1038/s41390-025-04676-9. PMID: 41193819. Abstract […]

Bleeding Disorders

Phase 3 Clinical Trial Results Indicate Efficacy of Marstacimab in Hemophilia A & B With Inhibitors

Click here for the open-access results of the anti-TFPI MOAB rebalancing therapy marstacimab (HYMPAVZI®): Matino D, Acharya SS, Taylor CT, et al. Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. Blood. 2026;147:920–31. doi: 10.1182/blood.2025031065. PMID: 41351884. Abstract Marstacimab, a monoclonal antibody that inhibits tissue factor […]

Bleeding Disorders

Review: Acquired Hemostasis Disorders

See this open-access review on acquired hemostasis disorders: Tufano A, Franchini M, Coppola A. Acquired hemostasis disorders. Semin Thromb Hemost. 2026;52:277–9. doi: 10.1055/a-2788-1844. PMID: 41802449.

Bleeding Disorders

Anticoagulant Monitoring in ECMO

Here’s a provocative open-access essay that reviews the efficacy of current anticoagulant monitoring in ECMO: Rajsic S, Treml B. Anticoagulation monitoring during ECMO support: monitor or flip a coin? Clin Cardiol. 2024;47(12):e70061. doi: 10.1002/clc.70061. PMID: 39692163; PMCID: PMC11653157. Abstract Should we rely on anticoagulation monitoring in ECMO patients or simply flip a coin? The increasing […]

Comments (0)

Anticoagulant Therapy

Mar 10 2026

george

BioMarin Withdraws Roctavian

This announcement appears in BioMarin’s 2025 full-year financial report: “Following the company’s October announcement to explore options to divest ROCTAVIAN, BioMarin undertook a comprehensive effort to identify a potential buyer. Despite these efforts, BioMarin was unable to identify a qualified buyer and has decided to withdraw ROCTAVIAN from the market voluntarily.” There are no FVIII […]

Comments (0)

Bleeding Disorders

All Posts

Review: Normal V. Elevated D-dimers and “D-dimeritis”

Case Study: VWF Inhibitors in Brothers

Meta-analysis: BAT in VWD Dx

Review and History: Protamine and Gene Therapy

Review: Antiphospholipid Antibodies and Cardiovascular Thrombosis

Effects of Platelet Transfusions on Neonates

Phase 3 Clinical Trial Results Indicate Efficacy of Marstacimab in Hemophilia A & B With Inhibitors

Review: Acquired Hemostasis Disorders

Anticoagulant Monitoring in ECMO

BioMarin Withdraws Roctavian

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question